Axcella to Present at Upcoming Investor Conferences

Rhea-AI Summary

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the 33rd Annual Roth Conference on March 15, 2021. Webcasts of these presentations will be available on the company’s website for 90 days. Axcella focuses on treating complex diseases using endogenous metabolic modulator compositions, with candidates targeting non-alcoholic steatohepatitis and hepatic encephalopathy.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will participate in the following upcoming investor conferences:

• SVB Leerink 10th Annual Global Healthcare Conference: The company’s fireside chat will be webcast on February 26, 2021 at 9:20 a.m. ET.
• H.C. Wainwright Global Life Sciences Conference: The company’s presentation will be webcast on March 9, 2021 at 7:00 a.m. ET.
• 33rd Annual Roth Conference: The company’s fireside chat will be webcast on March 15, 2021 at 9:00 a.m. ET.

The audio webcasts will be accessible on the “Investors & News” section of the company’s website, www.axcellahealth.com, for 90 days following the presentations.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005026/en/

FAQ

What is Axcella's upcoming conference schedule?

Axcella will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the 33rd Annual Roth Conference on March 15, 2021.

How can I access Axcella's conference webcasts?

The audio webcasts can be accessed on Axcella's website in the 'Investors & News' section for 90 days following the presentations.

What are Axcella's main therapeutic targets?

Axcella's pipeline includes therapeutic candidates for non-alcoholic steatohepatitis (NASH) and for reducing the risk of overt hepatic encephalopathy (OHE) recurrence.

What does Axcella specialize in?

Axcella specializes in developing endogenous metabolic modulator (EMM) compositions aimed at treating complex diseases and improving health.

What is the significance of Axcella's participation in investor conferences?

Axcella's participation in investor conferences provides an opportunity to present its clinical advancements and engage with investors, enhancing visibility in the biotechnology sector.